Genentech have announced that its ongoing Phase III study of Avastin (bevacizumab) in patients with early-stage colon cancer will continue as planned.
Filed under: Uncategorized | Tagged: Avastin, bevacizumab, Genentech, kinase, phase iii, Roche, VEGF | Comments Off
Phase III trial results show treatment with Avastin/Tarceva in patients with advanced NSCLC did not meet its primary endpoint (overall survival compared to Tarceva). Secondary endpoints of progression-free survival (PFS) and response rate when Avastin was added to Tarceva were however met.
Filed under: Uncategorized | Tagged: Avastin, bevacizumab, ErbB-1, ErbB1, erlotinib, Genentech, kinase, OSI, phase iii, Roche, Tarceva, VEGF | Comments Off
Data presented at the European of Medical Oncology (ESMO) show Avastin (bevacizumab) is the only biologic to provide overall survival (OS) benefit when used as first-line treatment in combination with chemotherapy for patients with K-Ras wild type metastatic colorectal cancer (mCRC).
Filed under: kinase | Tagged: Avastin, bevacizumab, Genentech, kinase, Roche, VEGF | Comments Off
Roche have announced that 100+ abstracts on Roche medicines will be presented at the upcoming European Society for Medical Oncology (ESMO) meeting.
Key presentations include:
* Data from AVAiL, confirming the use of Avastin as first line treatment in NSCLC
* Phase III data on continuation of Herceptin treatment
* Phase II data data on the use of [...]
Filed under: kinase | Tagged: Avastin, bevacizumab, Genentech, HER2, Herceptin, kinase, Phase II, phase iii, Roche, Trastuzumab, VEGF | Comments Off
Roche have issued a statement saying it won’t lower the price for Avastin despite UK’s NICE ruling that it is not a cost-effective treatment for advanced and/or metastatic renal cell carcinoma. Roche argue that Avastin is used in many cancer types and is fully reimbursed in most European countries.
Pfizer, Bayer and Wyeth are still considering their formal [...]
Filed under: kinase | Tagged: Avastin, bevacizumab, Genentech, kinase, NICE, regulatory, Roche, VEGF | Comments Off
The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary ruling stating that Avastin, Nexavar, Sutent and Torisel are not effective enough to warrant their high cost and shouldn’t be prescribed to new patients in Britain.
Filed under: Kinase receptor, kinase | Tagged: kinase, sunitinib, sutent, multikinase, SU11248, SU-11248, Pfizer, Genentech, Nexavar, sorafenib, onyx, bayer, VEGF, Wyeth, Roche, Avastin, bevacizumab, mTOR, torisel, temsirolimus, regulatory | Comments Off
Combining Sorafenib and Bevacizumab has been shown to increase antitumur activity in patients with advanced solid tumors, especially those with ovarian cancer.
Filed under: kinase | Tagged: kinase, multikinase, Genentech, Nexavar, sorafenib, onyx, bayer, VEGF, Roche, Avastin, bevacizumab, raf, RET, VEGFR, PDGFR | Comments Off
Genentech have halted its trial of Avastin in combination with Sutent following reports of several cases of microangiopathic hemolytic anemia (MAHA) in patients with solid tumors
Filed under: kinase | Tagged: Adverse effect, Avastin, bevacizumab, Genentech, kinase, multikinase, Pfizer, Roche, SU-11248, SU11248, sunitinib, sutent, VEGF | Comments Off
The UK NICE have announced that review of Avastin and Erbitux for the following indications have been terminated due to lack of data provision by their manufacturers:
- bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer
- bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with inoperable advanced, [...]
Filed under: kinase | Tagged: Avastin, bevacizumab, cetuximab, erbitux, Guidance, NICE | Comments Off
